Literature DB >> 15326167

Allosteric activation of antithrombin critically depends upon hinge region extension.

Jonathan Langdown1, Daniel J D Johnson, Trevor P Baglin, James A Huntington.   

Abstract

Antithrombin (AT) inhibits most of the serine proteases generated in the blood coagulation cascade, but its principal targets are factors IXa, Xa, and thrombin. Heparin binding to AT, via a specific pentasaccharide sequence, alters the conformation of AT in a way that promotes efficient inhibition of factors IXa and Xa, but not of thrombin. The conformational change most likely to be relevant to protease recognition is the expulsion of the N-terminal portion of the reactive center loop (hinge region) from the main beta-sheet A. Here we investigate the hypothesis that the exosites on the surface of AT are accessible for interaction with a protease only when the hinge region is fully extended, as seen in the related Michaelis complex between heparin cofactor II and thrombin. We engineered a disulfide bond between residues 222 on strand 3A and 381 in the reactive center loop to prevent the extension of the hinge region upon pentasaccharide binding. The disulfide bond did not significantly alter the ability of the variant to bind to heparin or to inhibit thrombin. Although the basal rate of factor Xa inhibition was not affected, that of factor IXa inhibition was reduced to the limit of detection. In addition, the disulfide bond completely abrogated the pentasaccharide accelerated inhibition of factors Xa and IXa. We conclude that AT hinge region extension is the activating conformational change for inhibition of factors IXa and Xa, and propose models for the progressive and activated AT Michaelis complexes with thrombin, factor Xa, and factor IXa.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15326167     DOI: 10.1074/jbc.M408961200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.

Authors:  Ivan Stevic; Howard H W Chan; Leslie R Berry; Ankush Chander; Anthony K C Chan
Journal:  J Biochem       Date:  2012-10-24       Impact factor: 3.387

Review 2.  Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations.

Authors:  Sean Garvin; Daniel Fitzgerald; Jochen D Muehlschlegel; Tjörvi E Perry; Amanda A Fox; Stanton K Shernan; Charles D Collard; Sary Aranki; Simon C Body
Journal:  Anesth Analg       Date:  2010-02-08       Impact factor: 5.108

3.  Structural and inhibitory effects of hinge loop mutagenesis in serpin-2 from the malaria vector Anopheles gambiae.

Authors:  Xin Zhang; David A Meekins; Chunju An; Michal Zolkiewski; Kevin P Battaile; Michael R Kanost; Scott Lovell; Kristin Michel
Journal:  J Biol Chem       Date:  2014-12-17       Impact factor: 5.157

4.  Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation.

Authors:  Daniel J D Johnson; Wei Li; Ty E Adams; James A Huntington
Journal:  EMBO J       Date:  2006-04-13       Impact factor: 11.598

5.  Molecular basis of factor IXa recognition by heparin-activated antithrombin revealed by a 1.7-A structure of the ternary complex.

Authors:  Daniel J D Johnson; Jonathan Langdown; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

6.  The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin.

Authors:  Jonathan Langdown; Klara J Belzar; Wendy J Savory; Trevor P Baglin; James A Huntington
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

7.  Engineering functional antithrombin exosites in alpha1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa.

Authors:  Gonzalo Izaguirre; Alireza R Rezaie; Steven T Olson
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

8.  A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.

Authors:  Zoya Volovyk; Dougald M Monroe; YiWei Qi; Richard Becker; Maureane Hoffman
Journal:  J Thromb Thrombolysis       Date:  2009-08       Impact factor: 2.300

Review 9.  Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery.

Authors:  Masahiro Ide; Daniel Bolliger; Taro Taketomi; Kenichi A Tanaka
Journal:  J Anesth       Date:  2009-12-29       Impact factor: 2.078

10.  Conformational change in the chromatin remodelling protein MENT.

Authors:  Poh Chee Ong; Sarah J Golding; Mary C Pearce; James A Irving; Sergei A Grigoryev; Debbie Pike; Christopher G Langendorf; Tanya A Bashtannyk-Puhalovich; Stephen P Bottomley; James C Whisstock; Robert N Pike; Sheena McGowan
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.